FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 303:188-191 July 24, 1980 Number 4 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We studied the incidence of malignant thyroid tumors after 131I therapy in 2727 patients with hyperthyroidism and in 273 euthyroid patients with cardiac disease. The patients were all adults, with a mean age of 57 years. The 131I therapy was given between 1951 and 1965. The mean follow-up period was 13 years for the hyperthyroid patients (15 years for the 85 per cent surviving for more than five years) and six years for the cardiac patients (12 years for the 41 per cent surviving for more than five years). The incidence of malignant thyroid tumors was based on a search of the Swedish Cancer Registry for the occurrence of such tumors in any of the 3000 patients. At present there is no increased incidence of malignant thyroid tumors after 131I therapy (four cases observed versus 3.2 cases expected).

This article has been cited by other articles:

• Davis, S., Kopecky, K. J., Hamilton, T. E., Onstad, L., and the Hanford Thyroid Disease Study Team, (2004). Thyroid Neoplasia, Autoimmune Thyroiditis, and Hypothyroidism in Persons Exposed to Iodine 131 From the Hanford Nuclear Site. JAMA 292: 2600-2613 [Abstract] [Full Text]  
• Streetman, D. D, Khanderia, U. (2003). Diagnosis and Treatment of Graves Disease. The Annals of Pharmacotherapy 37: 1100-1109 [Abstract] [Full Text]  
• Rivkees, S. A., Sklar, C., Freemark, M. (1998). The Management of Graves' Disease in Children, with Special Emphasis on Radioiodine Treatment. J. Clin. Endocrinol. Metab. 83: 3767-3776 [Full Text]  
• Cooper, D. S. (1998). Radioiodine for Hyperthyroidism: Where Do We Stand After 50 Years?. JAMA 280: 375-376 [Full Text]